Abstract
Anand et al, 1 in their fine article in the February 1993 issue of theArchives, describe the efficacy of an intravitreal sustained-release device containing ganciclovir to control CMV retinitis in patients with acquired AIDS. However, these authors did not report on the survival time of their 22 patients after the diagnosis of CMV retinitis. According to the data provided by Anand et al1 (p225) in Figure 1, we calculated median survival time using the Kaplan-Meier method for the 22 reported patients. Median survival time after diagnosis of CMV retinitis was 5.6 months ( Figure ). In contrast, as shown by several studies, median survival time in patients treated with either intravenously administered ganciclovir or foscarnet varies between 8 and more than 12 months. 2,3 Therefore, survival time in patients treated with the intravitreal sustained-release device appears to be shorter compared with patients treated with intravenously applied ganciclovir or foscarnet. In our
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
